ES2127758T3 - Nuevos inhibidores de la alfa-manosidasa. - Google Patents

Nuevos inhibidores de la alfa-manosidasa.

Info

Publication number
ES2127758T3
ES2127758T3 ES92918131T ES92918131T ES2127758T3 ES 2127758 T3 ES2127758 T3 ES 2127758T3 ES 92918131 T ES92918131 T ES 92918131T ES 92918131 T ES92918131 T ES 92918131T ES 2127758 T3 ES2127758 T3 ES 2127758T3
Authority
ES
Spain
Prior art keywords
manosidase
alpha
4alfa
beta
new inhibitors
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES92918131T
Other languages
English (en)
Inventor
Robert A Farr
Mohinder S Kang
Norton P Peet
Sai P Sunkara
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Aventis Pharmaceuticals Inc
Original Assignee
Merrell Dow Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merrell Dow Pharmaceuticals Inc filed Critical Merrell Dow Pharmaceuticals Inc
Application granted granted Critical
Publication of ES2127758T3 publication Critical patent/ES2127758T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D221/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00
    • C07D221/02—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00 condensed with carbocyclic rings or ring systems
    • C07D221/04—Ortho- or peri-condensed ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Immunology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Other In-Based Heterocyclic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Indole Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

LOS [4S-(4ALFA, 4ALFA-BETA, 6ALFA, 7ALFA, 7A-ALFA)]-OCTAHIDRO-1H-1PIRINDINA-4,5,6,7-TETROLES Y LOS [4R-(4ALFA, 4A-ALFA, 5ALFA, 6-BETA 7BETA, 7A-BETA)]-OCTAHIDRO-1H-1-PIRINDINA-4,5,6,7-TETROLES SON UTILES COMO INHIBIDORES DE ALFA-MANOSIDASA Y SON UTILES INMUNOESTIMULANTES, AGENTES QUIMIPROTECTORES Y RADIOPROTECTORES, Y AGENTES ANTIMETASTATICOS.
ES92918131T 1991-09-18 1992-08-10 Nuevos inhibidores de la alfa-manosidasa. Expired - Lifetime ES2127758T3 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US76157991A 1991-09-18 1991-09-18
US07/893,171 US5262425A (en) 1991-09-18 1992-06-03 α-mannosidase inhibitors

Publications (1)

Publication Number Publication Date
ES2127758T3 true ES2127758T3 (es) 1999-05-01

Family

ID=27117010

Family Applications (1)

Application Number Title Priority Date Filing Date
ES92918131T Expired - Lifetime ES2127758T3 (es) 1991-09-18 1992-08-10 Nuevos inhibidores de la alfa-manosidasa.

Country Status (15)

Country Link
US (1) US5262425A (es)
EP (1) EP0641327B1 (es)
JP (1) JP3226173B2 (es)
KR (1) KR100244012B1 (es)
AT (1) ATE175960T1 (es)
AU (1) AU659486B2 (es)
CA (1) CA2116224C (es)
DE (1) DE69228259T2 (es)
DK (1) DK0641327T3 (es)
ES (1) ES2127758T3 (es)
FI (1) FI105270B (es)
GR (1) GR3029745T3 (es)
HU (1) HU216789B (es)
NO (1) NO300372B1 (es)
WO (1) WO1993005781A1 (es)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5773239A (en) * 1993-10-19 1998-06-30 Mount Sinai Hospital Corporation. Mannosidase inhibitors, process for their preparation and their use as therapeutic agents
US5650413A (en) * 1995-06-07 1997-07-22 Glycodesign Inc. Derivatives of swainsonine, processes for their preparation and their use as therapeutic agents
US6048870A (en) * 1996-10-01 2000-04-11 Glycodesign 3, 5, and/or 6 substituted analogues of swainsonine processes for their preparation and their use as therapeutic agents
US6395745B1 (en) 1997-04-15 2002-05-28 Glycodesign, Inc. Alkaloid halide salts of swainsonine and methods of use
US6245316B1 (en) 1997-10-08 2001-06-12 David Platt Enhancement of delivery of radioimaging and radioprotective agents
WO1999021858A1 (en) * 1997-10-24 1999-05-06 Glycodesign Inc. Synthesis of swainsonine salts

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4031102A (en) * 1972-10-21 1977-06-21 John Wyeth & Brother Limited Cyclopenteno[b]pyridine derivatives
GB2088860B (en) * 1980-12-09 1984-05-23 Wyeth John & Brother Ltd Process for preparing ring-fused pyridine derivatives

Also Published As

Publication number Publication date
AU2477192A (en) 1993-04-27
NO300372B1 (no) 1997-05-20
JPH06510785A (ja) 1994-12-01
JP3226173B2 (ja) 2001-11-05
WO1993005781A1 (en) 1993-04-01
AU659486B2 (en) 1995-05-18
FI941259L (fi) 1994-03-17
DK0641327T3 (da) 1999-09-13
GR3029745T3 (en) 1999-06-30
EP0641327A1 (en) 1995-03-08
CA2116224A1 (en) 1993-04-01
US5262425A (en) 1993-11-16
HU216789B (hu) 1999-08-30
KR100244012B1 (ko) 2000-03-02
EP0641327A4 (en) 1994-06-01
EP0641327B1 (en) 1999-01-20
NO940972L (no) 1994-03-17
NO940972D0 (no) 1994-03-17
HUT70527A (en) 1995-10-30
FI941259A0 (fi) 1994-03-17
HU9400787D0 (en) 1994-06-28
ATE175960T1 (de) 1999-02-15
FI105270B (fi) 2000-07-14
CA2116224C (en) 2003-06-03
DE69228259D1 (de) 1999-03-04
DE69228259T2 (de) 1999-06-02

Similar Documents

Publication Publication Date Title
ES2161220T3 (es) 9-((glicil sustituido)amido)-6-desmetil-6-desoxitetraciclinas como agentes antibioticos.
CY1108610T1 (el) Πεπτιδια της il-2 και παραγωγα αυτων και χρηση αυτων ως θεραπευτικοι παραγοντες
ES2184797T3 (es) Uso de antagonistas de serotonina (5ht3) para el tratamiento de la fibromialgia.
PA8468401A1 (es) Compuestos para el tratamiento de la isquemia
CO4290353A1 (es) Agonistas de estrogeno
YU48666B (sh) Mometason furoat monohidrat i postupak za njegovo dobijanje
MX9700557A (es) Dihidrobenzofuranos.
FI904101A7 (fi) 17B-asyyli-4-atsa-5a-androst-1-en-3-en-3-oneja 5a-reduktaasi-inhibiittoreina
ES2191208T3 (es) Oxiimino-pregnano-carbolactonas.
ES2063102T3 (es) Imidazoles para el tratamiento de la aterosclerosis.
ES2183331T3 (es) Inhibidores de sulfamida-metaloproteasa.
ES2071169T3 (es) 1-indolilalquil-4-(alcoxi-pirimidinil)piperazinas.
ES2089687T3 (es) 4-fenil-piridonas y 4-fenil-2-alcoxipiridinas sustituidas como inhibidores de la hmg-coa-reductasa.
MXPA94001345A (es) Derivados de poliamina como agentes radioprotectores.
ES2151168T3 (es) N-(2,4-dioxo-2,3,4,5-tetrahidro-1h-1,5-benzodiazepin-3-il)-3-amidas.
ES2147427T3 (es) Aminas ciclicas n-sustituidas, su procedimiento de preparacion y las composiciones farmaceuticas que las contienen.
ES2144666T3 (es) Nuevos derivados de n-acil 2-arilciclopropilmetilamina como agentes melatonergicos.
ATE258789T1 (de) 5-ht2-antagonisten in der behandlung venöser zustände
ES2091712B1 (es) Asociaciones sinergizantes que tienen un efecto antagonista de los receptores nk1 y nk2.
ES2167678T3 (es) Tratamiento y profilaxis de la pancreatitis.
ES2157899T3 (es) Derivados de sampangina utiles como agentes antifungicos y antimicobacterianos.
MX9700854A (es) Derivados de azabicicloheptano n-substituidos utiles como neurolepticos.
ES2140672T3 (es) Compuestos biciclicos sustituidos, fusionados y puentes utilizados como agentes terapeuticos.
ES2141978T3 (es) Retinoides triciclicos, metodos para su produccion y uso.
ATE28188T1 (de) Antikonvulsive mittel.

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 641327

Country of ref document: ES